ERBB2 and breast cancer: Notably, HR+/HER2- breast cancer patients with high KPNA2 but low FOXM1 mRNA levels showed significantly better survival outcomes (OS: p = 0.0355; DSS: p = 0.0424), suggesting a novel prognostic signature for this major breast cancer subtype.